...
首页> 外文期刊>CNS neuroscience & therapeutics. >Successful Combined Therapy with Tamoxifen and Lithium in a Paradoxical Sleep Deprivation‐Induced Mania Model
【24h】

Successful Combined Therapy with Tamoxifen and Lithium in a Paradoxical Sleep Deprivation‐Induced Mania Model

机译:在反常睡眠剥夺引起的躁狂症模型中成功与他莫昔芬和锂联合治疗

获取原文
   

获取外文期刊封面封底 >>

       

摘要

SUMMARY Background: Previous studies have suggested that manic states and sleep deprivation could contribute to the pathophysiology of bipolar disorder (BD) through protein kinase C (PKC) signaling abnormalities. Moreover, adjunctive therapy has become a standard strategy in the management of BD patients who respond poorly to current pharmacological treatments. Aim: Thus, the aim of this study was to investigate the possible involvement of PKC inhibition by tamoxifen both separately or in combination with lithium, in paradoxical sleep deprivation (PSD)‐induced hyperactivity, one facet of mania‐like behavior. Materials & Methods: Adult male C57BL/6J mice were randomly distributed (n = 7/group) in 24‐h PSD or control groups and injected intraperitoneally (i.p.) with vehicle, lithium (50, 100, or 150 mg/kg) or tamoxifen (0.5, 1.0, or 2.0 mg/kg – experiment 1). In a second experiment, mice were injected i.p. with vehicle or a combination of subeffective doses of lithium and tamoxifen. Animals were subjected to a protocol based on repetitive PSD conditions, followed by assessment of locomotion activity in the open‐field task. Results: PSD significantly increased locomotor activity in both experiments. These behavioral changes were prevented by a treatment with lithium or tamoxifen, or a combined treatment with both lithium and tamoxifen. Discussion: Therefore, our findings suggest that lithium and tamoxifen exert reversal effects against PSD‐induced hyperactivity in mice. Conclusion: Furthermore, tamoxifen as an adjunct to lithium therapy provides support for an alternative treatment of individuals who either do not respond adequately or cannot tolerate the adverse effects associated with therapeutic doses of lithium.
机译:概述背景:先前的研究表明,躁狂状态和睡眠剥夺可能通过蛋白激酶C(PKC)信号异常来促进躁郁症(BD)的病理生理。此外,辅助疗法已成为治疗对当前药物治疗反应不佳的BD患者的标准策略。目的:因此,本研究的目的是研究他莫昔芬单独或与锂组合对PKC抑制作用可能与反常睡眠剥夺(PSD)引起的多动症(一种躁狂样行为)有关。材料与方法:成年雄性C57BL / 6J小鼠随机分为24小时PSD或对照组(每组7只),并腹膜内(ip)注射溶媒,锂(50、100或150 mg / kg)或他莫昔芬(0.5、1.0或2.0 mg / kg –实验1)。在第二个实验中,腹膜内注射小鼠。媒介物或亚有效剂量的锂和他莫昔芬的组合。根据重复的PSD条件对动物进行实验,然后在野外任务中评估运动活动。结果:在两个实验中,PSD均显着提高了运动活性。锂或他莫昔芬治疗或锂和他莫昔芬联合治疗可预防这些行为改变。讨论:因此,我们的发现表明,锂和他莫昔芬对PSD诱导的小鼠活动亢进具有逆转作用。结论:此外,他莫昔芬作为锂疗法的辅助手段,为那些反应不佳或无法耐受锂治疗剂量相关不良反应的个体提供了替代疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号